Immunome Inc. (IMNM) insider buying and SEC filings
Immunome Inc. · CIK 1472012
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$1.3M
Insiders who bought
3
Sold (not marked 10b5-1)
$1.5M
Planned sales (10b5-1)
$26.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 11, 2026 | Planned (10b5-1) | Jack Higgins (Chief Scientific Officer) sold 13,200 shares at $25.32 ($334K), marked as a 10b5-1 plan trade. Holdings down 17% to 65,050 shares. | SEC filing Filed Sep 15, 2026 |
| Aug 10–12, 2026 | Planned (10b5-1) | Isaac Barchas (Director) sold 83,464 shares directly and indirectly between Aug 10 and Aug 12 at about $26.35 ($2.2M), marked as a 10b5-1 plan trade. Direct holdings down 11% to 92,211 shares. | SEC filing Filed Aug 12, 2026 |
| Aug 6–7, 2026 | Planned (10b5-1) | Isaac Barchas (Director) sold 36,088 shares indirectly between Aug 6 and Aug 7 at about $26.06 ($940K), marked as a 10b5-1 plan trade. Indirect holdings down 33% to 72,416 shares. | SEC filing Filed Aug 10, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Kinney Horn (Chief Business Officer) sold 90,616 shares at about $25.09 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Aug 6, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Kinney Horn (Chief Business Officer) sold 1,092 shares at $25.00 ($27K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jul 9, 2026 |
| Jul 6–7, 2026 | Planned (10b5-1) | Isaac Barchas (Director) sold 100,000 shares indirectly between Jul 6 and Jul 7 at about $24.13 ($2.4M), marked as a 10b5-1 plan trade. Indirect holdings down 48% to 108,504 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Robert Lechleider (Chief Medical Officer) sold 55,000 shares at about $22.62 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 78% to 15,805 shares. | SEC filing Filed Jul 7, 2026 |
| Jun 30–Jul 2, 2026 | Planned (10b5-1) | Isaac Barchas (Director) sold 201,050 shares indirectly between Jun 30 and Jul 2 at about $21.85 ($4.4M), marked as a 10b5-1 plan trade. Indirect holdings down 25% to 308,504 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Robert Lechleider (Chief Medical Officer) sold 55,000 shares at about $19.85 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 78% to 15,805 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Max Rosett (CFO) sold 60,000 shares at about $18.23 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 53% to 54,037 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 5, 2026 | Sale | Jean Jacques Bienaime (Director) sold 10,500 shares at about $19.41 ($204K). Holdings down 24% to 32,915 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 9, 2026 |
| Jun 5, 2026 | Purchase (code P) | Jean Jacques Bienaime (Director) bought 10,500 shares at about $19.45 ($204K), reported as a purchase (code P). Holdings up 32% to 43,415 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 9, 2026 |
| May 15, 2026 | Purchase (code P) | Jean Jacques Bienaime (Director) bought 5,000 shares at about $20.70 ($104K), reported as a purchase (code P). Holdings up 13% to 43,415 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Max Rosett (CFO) sold 65,000 shares at about $21.92 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 55% to 54,037 shares. | SEC filing Filed Apr 3, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Jack Higgins (Chief Scientific Officer) sold 9,438 shares at $21.64 ($204K), marked as a 10b5-1 plan trade. Holdings down 30% to 22,000 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 27, 2026 | Purchase (code P) | Clay B. Siegall (CEO and Director) bought 25,450 shares at about $19.67 ($501K), reported as a purchase (code P). Holdings up 4% to 690,704 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 31, 2026 |
| Mar 20–23, 2026 | Sale | Philip Wagenheim (Director) sold 65,000 shares between Mar 20 and Mar 23 at about $20.55 ($1.3M). Holdings down 16% to 341,147 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 23, 2026 |
| Mar 10–11, 2026 | Purchase (code P) | Jean Jacques Bienaime (Director) bought 2,000 shares between Mar 10 and Mar 11 at about $21.84 ($44K), reported as a purchase (code P). Holdings up 5% to 38,415 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 12, 2026 |
| Dec 30, 2025 | Purchase (code P) | Clay B. Siegall (CEO and Director) bought 4,729 shares at $21.15 ($100K), reported as a purchase (code P). Holdings up 1% to 665,254 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 30, 2025 |
| Dec 22, 2025 | Planned (10b5-1) | Isaac Barchas (Director) sold 383,200 shares indirectly at about $21.74 ($8.3M), marked as a 10b5-1 plan trade. Indirect holdings down 15% to 2,042,432 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 19, 2025 | Purchase (code P) | Philip Tsai (Chief Technical Officer) bought 10,000 shares at $20.49 ($205K), reported as a purchase (code P). Holdings up 30% to 43,300 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 22, 2025 |
| Dec 19, 2025 | Purchase (code P) | Clay B. Siegall (CEO and Director) bought 7,278 shares at about $20.48 ($149K), reported as a purchase (code P). Holdings up 1% to 860,525 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 22, 2025 |
| Dec 18, 2025 | Other purchase | Clay B. Siegall (CEO and Director) bought 46,511 Common Stock at $21.50 ($1.0M) in a public offering. Holdings up 6% to 853,247 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 18, 2025 |
23 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$544K in purchases since Mar 11, 2026 · Purchases traded Mar 11, 2026 to Mar 27, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Jean Jacques Bienaime (Director) | $44K | Mar 11, 2026 | SEC filing |
| Clay B. Siegall (CEO) | $501K | Mar 27, 2026 | SEC filing |
2 insiders bought in 30 days
$454K in purchases since Dec 19, 2025 · Purchases traded Dec 19, 2025 to Dec 30, 2025 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Clay B. Siegall (CEO) | $149K | Dec 19, 2025 | SEC filing |
| Philip Tsai (Chief Technical Officer) | $205K | Dec 19, 2025 | SEC filing |
| Clay B. Siegall (CEO) | $100K | Dec 30, 2025 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow IMNM in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.